Prostate Cancer Foundation

donate ribbon

Donate Now    FAQs   Contact Us   Español   twitter   facebook

Navigation

Prostate Cancer Research

Young Investigator Award Recipients 2011 - Andrew Goldstein, PhD

The 2011 Joe and Ali Torre – PCF Young Investigator Award (first year)

The 2011 Bonnie Pfeifer Evans – PCF Young Investigator Award (second year)

The 2011 Todd Boehly – PCF Young Investigator Award

Andrew Goldstein, PhD
University of California, Los Angeles

The first medical treatment for metastatic prostate cancer is Androgen Deprivation Therapy (ADT). Unfortunately, nearly 100% of patients become refractory to this treatment and their cancer progresses to androgen-independent, castration-resistant stage (CRPC). Eliminating the CRPC-regenerating tumor cell population might inhibit disease recurrence; however, it is unclear if such a population exists. Dr. Andrew Goldstein has developed a direct transformation assay that can re-program normal human prostate cells to reconstitute human prostate cancer in immunodeficient mice. Ultimately, he proposes to use this model to investigate various genetic drivers to castration resistance and is studying the mechanisms that lead to the development of castration-resistant prostate cancer with a focus on treatment targets that will reverse lethality of the disease.

Mentor: Owen Witte, MD


Facebook Users: Please note that your comment or profile will not be posted to this page, or to Facebook, until you click the “Comment” button. If you do not want your comment to be posted to Facebook, please uncheck the “Post to Facebook” checkbox.

Print | Bookmark and Share

2000 Programs Worldwide

Progress Reports

prostate cancer guides and books

prostate cancer clinical trials

patient support

athletes for a cure